Regeneron Pharmaceuticals Inc
(MIL:1REGN)
€
757
-25.2 (-3.22%)
Market Cap: 83.82 Bil
Enterprise Value: 77.30 Bil
PE Ratio: 20.53
PB Ratio: 3.11
GF Score: 79/100 
Regeneron Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020 / 02:00PM GMT
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
Hey, everybody. It's Alethia Young here. I cover large-cap biotech at Cantor, and I'm one of the small and midcap analysts here as well. Obviously, it doesn't really need an introduction, but I'm very happy to have Regeneron Pharmaceuticals here. We will do a fireside chat. I have with me Israel Lowy, who's the Senior Vice President, Translational Sciences and Oncology; and Justin Holko, who is VP and Head of Investors.
Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR
All right. I hear you.
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
Okay. You got us. We're good. Okay.
Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR
Sorry. I'm so sorry.
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
It's okay. No worries. We're
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers